JPRN-jRCT2080222774未知3 期
An open label extension study of phase 3 clinical trial of duloxetine in patients with osteoarthritis
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •Consecutive Participants:
- •Participants who have completed the 15-week treatment in the preceding study (A phase 3 clinical trial of duloxetine in patients with osteoarthritis)
- •New Participants:
- •Participants meet the ACR criteria for idiopathic osteoarthritis of the knee.
排除标准
- •Participants having a confounding painful condition that may interfere with assessment of the joint.
研究者
相似试验
未知
3 期
An open label extension study of phase 3 clinical trial of duloxetine in patients with chronic low back paiJPRN-jRCT2080222263SHIONOGI & CO., LTD.
已完成
3 期
An open-label extension study of duloxetine in children and adolescents with depressive disorderDepressive disorderJPRN-jRCT2080223797Shionogi & Co., Ltd.135
未知
3 期
An Open Label Extension Study of Phase III Clinical Trial of Duloxetine in Patients With FibromyalgiaFibromyalgiaJPRN-jRCT2080221803SHIONOGI & CO., LTD.
进行中（未招募）
1 期
This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the M16-046 study. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the timeframe of Study M16-046. There will be a 30 day follow-up visit after the treatment period is completedModerate to severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2019-001227-12-IEAbbVie Deutschland GmbH & Co. KG485
进行中（未招募）
1 期
This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the M16-046study. At the end of M16-046, they have the option to receive Upadacitinib until the investigational drug has been approved by the regulatory authorities in their country and/or applicable local reimbursement approval. There will be a 30 day follow-up visit after the treatment period is completedModerate to severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2019-001227-12-HUAbbVie Deutschland GmbH & Co. KG485